Literature DB >> 10964653

Prion disease: A loss of antioxidant function?

B S Wong1, T Pan, T Liu, R Li, R B Petersen, I M Jones, P Gambetti, D R Brown, M S Sy.   

Abstract

Prion disease, a neurodegenerative disorder, is widely believed to arise when a cellular prion protein (PrP(C)) undergoes conformational changes to a pathogenic isoform (PrP(Sc)). Recent data have shown PrP(C) to be copper binding and that it acquires antioxidant activity as a result. This enzymatic property is dependent mainly on copper binding to the octarepeats region. In normal human brain and human prion disease, there is a population of brain-derived PrP that has been truncated at the N-terminal which encompassed the octarepeats region. Increasing evidences have suggested imbalances of metal-catalyzed reactions to be the common denominator for several neurodegenerative diseases. Therefore, we propose that one of the causative factors for prion disease could be due to the imbalances in metal-catalyzed reactions resulting in an alteration of the antioxidant function. These result in an increase level of oxidative stress and, as such, trigger the neurodegenerative cascade. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964653     DOI: 10.1006/bbrc.2000.3158

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Prion proteins and the gut: une liaison dangereuse?

Authors:  A N Shmakov; S Ghosh
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

2.  Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia.

Authors:  Eckhard Flechsig; Ivan Hegyi; Rainer Leimeroth; Armando Zuniga; Daniela Rossi; Antonio Cozzio; Petra Schwarz; Thomas Rülicke; Jürgen Götz; Adriano Aguzzi; Charles Weissmann
Journal:  EMBO J       Date:  2003-06-16       Impact factor: 11.598

3.  Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease.

Authors:  G Gossrau; B Herting; S Möckel; A Kempe; R Koch; H Reichmann; J B Lampe
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

4.  Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.

Authors:  Tao Pan; Poki Wong; Binggong Chang; Chaoyang Li; Ruliang Li; Shin-Chung Kang; Thomas Wisniewski; Man-Sun Sy
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  New molecular insights into cellular survival and stress responses: neuroprotective role of cellular prion protein (PrPC).

Authors:  Raymond Yen-Yu Lo; Woei-Cherng Shyu; Shinn-Zong Lin; Hsiao-Jung Wang; Shun-Sheng Chen; Hung Li
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 6.  Redox control of prion and disease pathogenesis.

Authors:  Neena Singh; Ajay Singh; Dola Das; Maradumane L Mohan
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

7.  Flotillin-1 mediates PrPc endocytosis in the cultured cells during Cu²⁺ stimulation through molecular interaction.

Authors:  Ke Ren; Chen Gao; Jin Zhang; Ke Wang; Yin Xu; Shao-Bin Wang; Hui Wang; Chan Tian; Qi Shi; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

8.  Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death.

Authors:  Christopher J Choi; Vellareddy Anantharam; Nathan J Saetveit; Robert S Houk; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Toxicol Sci       Date:  2007-05-04       Impact factor: 4.849

9.  Copper modulation of ion channels of PrP[106-126] mutant prion peptide fragments.

Authors:  J I Kourie; B L Kenna; D Tew; M F Jobling; C C Curtain; C L Masters; K J Barnham; R Cappai
Journal:  J Membr Biol       Date:  2003-05-01       Impact factor: 1.843

10.  Cellular prion protein transduces neuroprotective signals.

Authors:  Luciana B Chiarini; Adriana R O Freitas; Silvio M Zanata; Ricardo R Brentani; Vilma R Martins; Rafael Linden
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.